Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
First Claim
Patent Images
1. A method for diagnosis and monitoring a host response to infection, SIRS and sepsis, said method comprising (a) obtaining a patient sample;
- (b) measuring a lipoprotein fraction from said sample for an abnormality; and
(c) correlating said lipoprotein measurement to an abnormality found in patients having severe infection, SIRS or hemostatic dysfunction.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for diagnosing and monitoring subjects for hemostatic dysfunction, severe infection and systematic inflammatory response syndrome is provided whereby lipoproteins are examined for abnormalities, particularly for prothrominase enhancement, through quantitative and qualitative analysis.
-
Citations
25 Claims
-
1. A method for diagnosis and monitoring a host response to infection, SIRS and sepsis, said method comprising (a) obtaining a patient sample;
- (b) measuring a lipoprotein fraction from said sample for an abnormality; and
(c) correlating said lipoprotein measurement to an abnormality found in patients having severe infection, SIRS or hemostatic dysfunction. - View Dependent Claims (2, 3, 4, 5)
- (b) measuring a lipoprotein fraction from said sample for an abnormality; and
-
6. A method to predict an increased likelihood of system failure or mortality in said patient, said method comprising (a) obtaining a patient sample;
- (b) measuring from said sample a lipoprotein fraction for PTase;
(c) comparing said prothrombin activation of said sample to a standard of normal patient samples or abnormal patient samples; and
(d) utilizing said comparison to predict the mortality of said patient wherein said lipoprotein for supporting PTase for patients with increased likelihood of system failure or mortality demonstrates at least a two-fold increase in PTase activity as compared with normal samples.
- (b) measuring from said sample a lipoprotein fraction for PTase;
-
7. A method for predicting an increased likelihood of infection in a patient, said method comprising:
- (a) obtaining a sample of very large density lipoproteins (VLDLs) from a patient; and
(b) determining the activity of VLDLs in said plasma or serum sample for activating prothrombin;
a greater activity of said VLDLs for activating prothrombin indicating an increased likelihood of infection in said patient. - View Dependent Claims (8, 9, 10)
- (a) obtaining a sample of very large density lipoproteins (VLDLs) from a patient; and
-
11. A method for diagnosing severe infection, SIRS or sepsis, said method comprising (a) obtaining a patient sample;
- (b) subjecting the patient sample to a biphasic waveform screening test to obtain a normal or biphasic waveform result;
(c) subjecting said patient samples demonstrating said biphasic waveform result to a to determine PTase of the lipoproteins; and
(d) determining a relationship with those patients exhibiting increased PTase activities with a diagnosis of severe infection, SIRS or sepsis. - View Dependent Claims (13)
- (b) subjecting the patient sample to a biphasic waveform screening test to obtain a normal or biphasic waveform result;
-
12. The method according to claim 12, wherein said infection is sepsis.
-
14. A method for diagnosis and monitoring a host response to infection, SIRS and sepsis, said method comprising (a) obtaining a blood sample or serum sample from a patient;
- (b) measuring said sample lipoprotein fraction for qualitative or quantitative properties of lipoproteins utlizing an anlaysis comprising NMR;
(c) comparing said properties of lipoproteins of said sample to a standard of normal patient samples or abnormal patient samples; and
(d) utilizing said comparison to diagnose and/or monitor a host response to infection, SIRS and sepsis.
- (b) measuring said sample lipoprotein fraction for qualitative or quantitative properties of lipoproteins utlizing an anlaysis comprising NMR;
-
15. A specific binding assay diagnosing and monitoring patients with severe infection, SIRS and sepsis said method comprising (a) obtaining a sample from a patient;
- (b) contacting said sample with a specific binding agent to capture a lipoprotein containing an abnormality;
(c) quantitatively or qualitatively analzying said captured abnormal lipoprotein to obtain a result; and
(d) correlating said result with abnormal lipoproteins found in patients with severe infection, SIRS and hemostatic dysfunction. - View Dependent Claims (16, 17)
- (b) contacting said sample with a specific binding agent to capture a lipoprotein containing an abnormality;
- 18. A method for treating a patient for severe infection, SIRS or sepsis, said method comprising administering an effective amount of Annexin 5 to block prothrombinase assembly.
-
20. A method for predicting the existence of sepsis in a patient, said method comprising:
- a) obtaining a sample of lipoproteins from a patients, (b) determining whether the lipoproteins are abnormal as compared to lipoproteins from a normal patient sample, and (c) predicting the existence of sepsis in the patient based on detected abnormal lipoproteins.
-
22. A method for predicting the hemostatic dysfunction in a patient, said method comprising:
- a) obtaining a sample of lipoproteins from a patients, (b) determining whether the lipoproteins are abnormal as compared to lipoproteins from a normal patient sample, and (c) predicting the existence of hemostatic dysfunction in the patient based on detected abnormal lipoproteins.
-
23. A method according to claim 23 wherein said step (b) is carried out by detecting an enhanced procoagulant aspect of the VLDL from patients with the biphasic waveform by measuring a shortening of clot time in a modified APTT assay or measuring clot formation or measuring increased rate of accelaration of clot formation in a dilute tissue factor based assay.
-
24. A method for diagnosis and monitoring a host response to infection, SIRS and sepsis, said method comprising (a) obtaining a patient sample;
- (b) measuring a lipoprotein fraction from said sample for total surface area; and
(c) correlating said lipoprotein measurement to increased surface area lipoprotein abnormality found in patients having severe infection, SIRS and hemostatic dysfunction. - View Dependent Claims (25)
- (b) measuring a lipoprotein fraction from said sample for total surface area; and
Specification